Monika Buergler
+41 44 350 31 05


Saturday, September 5, 2020 from 8:30 AM to 6:00 PM CEST
Add to Calendar 

Course followed by dinner


Diergeneeskundig Centrum Hopmans

Diergeneeskundig Centrum Hopmans
Groene Zoom 2
9301 Roden SJ

Driving Directions 

Accomodation & Travel

Please contact Dr. Joop Hopmans for advice

Joop Hopmans

Join My Mailing List

Roden, Netherlands


– Review of rationale / theory
– Instruction in lecture / video / bone model format
– Technical / practical instruction
– Bone model exercises
– Wet lab exercises
– Ample discussion
– Presentations on clinical experience, advanced techniques, avoiding/managing complications, new/ongoing research

Joop Hopmans, DVM, private practice surgeon - Diergeneeskundig Centrum Hopmans, Roden, Netherlands


Diergeneeskundig Centrum Hopmans
Groene Zoom 2
9301 Roden SJ




CHF 1100.-


Payment can be made by credit card or bank transfer. Please contact Monika Buergler at


Hardturmstrasse 103
8005 Zurich, Switzerland
Phone: +41 44 350 31 05
Fax: +41 44 350 31 06

Tibial Tuberosity Advancement 2

Throughout the last decade of clinical experience, KYON continued to refine and improve TTA preoperative planning, surgical technique, implants and instruments. In 2012, KYON in collaboration with Dr. Joop Hopmans began in vitro testing and, soon after, safety and efficacy testing to explore the next step in the TTA evolution, TTA-2*. 

TTA-2 consists of an incomplete osteotomy, performed with a novel hinged saw guide and a new cage, designed to transfer shear and compression forces. The simplified surgical technique preserves the periosteum on the medial aspect of the tibial tuberosity, eliminates stress risers created by the plate, fork, and screws, shortens the surgery time, and reduces the implant inventory. 

TTA-2 implants are packaged sterile for surgical convenience. In vitro and in vivo studies have demonstrated that the saw guide and surgical planning for its use combined with the use of the Fine Touch Osteotomy Spreader minimizes the risk of intraoperative or early postoperative fracture of the tuberosity.

With 2 years of clinical experience and over a decade's experience in the basic mechanical and biological principles behind tibial tuberosity advancement as a geometry modifying procedure, TTA-2 was made commercially available in spring 2014. TTA-2 has the potential to reduce iatrogenic trauma, reduce the risk of infection, accelerate the incorporation of the implant into the bone and shorten the surgery time, thus providing surgeons and their patients with tangible benefits.

TTA-2 involves an incomplete osteotomy of the non-weight bearing portion of the tibia. The patellar ligament is aligned perpendicular to the common tangent of the femorotibial joint, eliminating cranial tibial thrust. This alignment takes the load off the CrCL even in full extension and results in a stable joint.

*Patented/Patent Pending